Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Ting Su

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
Neuro-Oncology Advances|July 10, 2020
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironmentYu-Ting Su, Madison Butler, Meili Zhang, et al.
Frontiers in Oncology|February 1, 2021
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post ImmunotherapyGuangyang Yu, Madison K Butler, Abdalla Abdelmaksoud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade AstrocytomasJing Wu, Ying Yuan, Debra A Long Priel, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
Neuro-Oncology Advances|July 10, 2020
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironmentYu-Ting Su, Madison Butler, Meili Zhang, et al.
Frontiers in Oncology|February 1, 2021
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post ImmunotherapyGuangyang Yu, Madison K Butler, Abdalla Abdelmaksoud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade AstrocytomasJing Wu, Ying Yuan, Debra A Long Priel, et al.
Pageof 12